CN110914274A - Radiopharmaceuticals, radioimaging agents and uses thereof - Google Patents
Radiopharmaceuticals, radioimaging agents and uses thereof Download PDFInfo
- Publication number
- CN110914274A CN110914274A CN201880037177.5A CN201880037177A CN110914274A CN 110914274 A CN110914274 A CN 110914274A CN 201880037177 A CN201880037177 A CN 201880037177A CN 110914274 A CN110914274 A CN 110914274A
- Authority
- CN
- China
- Prior art keywords
- compound
- complex
- salt
- solvate
- isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract description 8
- 239000012217 radiopharmaceutical Substances 0.000 title abstract description 7
- 229940121896 radiopharmaceutical Drugs 0.000 title abstract description 7
- 230000002799 radiopharmaceutical effect Effects 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 137
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 26
- 239000012453 solvate Substances 0.000 claims description 25
- 229940002612 prodrug Drugs 0.000 claims description 24
- 239000000651 prodrug Substances 0.000 claims description 24
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 23
- 239000010949 copper Substances 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 15
- 229910021645 metal ion Inorganic materials 0.000 claims description 15
- 150000001408 amides Chemical class 0.000 claims description 14
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 12
- 239000004202 carbamide Substances 0.000 claims description 12
- 229960005219 gentisic acid Drugs 0.000 claims description 12
- 210000003734 kidney Anatomy 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 229910052733 gallium Inorganic materials 0.000 claims description 3
- 229910052738 indium Inorganic materials 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 2
- 229910052765 Lutetium Inorganic materials 0.000 claims description 2
- 229910052793 cadmium Inorganic materials 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229910001431 copper ion Inorganic materials 0.000 claims description 2
- 229910052741 iridium Inorganic materials 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 229910052702 rhenium Inorganic materials 0.000 claims description 2
- 229910052707 ruthenium Inorganic materials 0.000 claims description 2
- 229910052706 scandium Inorganic materials 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 229910052721 tungsten Inorganic materials 0.000 claims description 2
- 229910052720 vanadium Inorganic materials 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 125000005156 substituted alkylene group Chemical group 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 15
- 238000003745 diagnosis Methods 0.000 abstract description 10
- 238000001959 radiotherapy Methods 0.000 abstract description 8
- 239000002738 chelating agent Substances 0.000 abstract description 3
- 238000002059 diagnostic imaging Methods 0.000 abstract description 2
- 238000004393 prognosis Methods 0.000 abstract description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 53
- 239000011347 resin Substances 0.000 description 40
- 229920005989 resin Polymers 0.000 description 40
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 35
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 35
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 230000027455 binding Effects 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- -1 alkoxyheteroaryl Chemical group 0.000 description 21
- 239000003446 ligand Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 229910001868 water Inorganic materials 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 14
- 238000003384 imaging method Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- 125000005647 linker group Chemical group 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 11
- 235000013877 carbamide Nutrition 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 230000008685 targeting Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000003608 radiolysis reaction Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 125000004404 heteroalkyl group Chemical group 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 229910003827 NRaRb Inorganic materials 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 150000003672 ureas Chemical class 0.000 description 4
- HNPWTDUZIXAJSA-UHFFFAOYSA-N 5,5-dimethyl-2-(3-methylbutanoyl)cyclohexane-1,3-dione Chemical compound CC(C)CC(=O)C1C(=O)CC(C)(C)CC1=O HNPWTDUZIXAJSA-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 229910002476 CuII Inorganic materials 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 239000003875 Wang resin Substances 0.000 description 3
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000003302 alkenyloxy group Chemical group 0.000 description 3
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000004465 cycloalkenyloxy group Chemical group 0.000 description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000000163 radioactive labelling Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- SJVFAHZPLIXNDH-JOCHJYFZSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-JOCHJYFZSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 2
- NVOVSXGZALWAFS-UHFFFAOYSA-N 3,6,10,13,16,19-hexazabicyclo[6.6.6]icosane Chemical compound C1NCCNCC2CNCCNCC1CNCCNC2 NVOVSXGZALWAFS-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QZQXRZXYWVQWAY-UHFFFAOYSA-N 8-(9h-fluoren-9-ylmethoxycarbonylamino)octanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCCCCCC(=O)O)C3=CC=CC=C3C2=C1 QZQXRZXYWVQWAY-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 125000001711 D-phenylalanine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 108010070783 alanyltyrosine Proteins 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000004171 alkoxy aryl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000005133 alkynyloxy group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000000262 haloalkenyl group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000000232 haloalkynyl group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- CBFCDTFDPHXCNY-UHFFFAOYSA-N icosane Chemical compound CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 description 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101001105692 Homo sapiens Pre-mRNA-processing factor 6 Proteins 0.000 description 1
- 241000102542 Kara Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 206010023849 Laryngeal papilloma Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- HBLBYUIRGKYTEF-UHFFFAOYSA-N O.FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.FC(C(=O)O)(F)F Chemical compound O.FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.FC(C(=O)O)(F)F HBLBYUIRGKYTEF-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100021232 Pre-mRNA-processing factor 6 Human genes 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 206010059394 acanthoma Diseases 0.000 description 1
- 229910052767 actinium Inorganic materials 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical group CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000009000 laryngeal papillomatosis Diseases 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000006335 response to radiation Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical class O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/08—Copper compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Nuclear Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to compounds useful as radiopharmaceuticals and radioimaging agents with radionuclide chelators. These coordination compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and treatment using the non-coordinating and radiolabeled compounds of the invention.
Description
FIELD
The present invention relates to compounds useful as radiopharmaceuticals and radioimaging agents containing radionuclide chelators. These coordination compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and treatment using the non-coordinating and radiolabeled compounds of the invention.
Technical Field
Prostate cancer is the leading cause of cancer-related death in men, and its mortality is often attributed to difficulties in the detection and subsequent treatment of the disease. Prostate-associated tumors often show increased expression of the Prostate Specific Membrane Antigen (PSMA), an enzyme that is commonly expressed in prostate tissue, but is often upregulated in certain prostate cancers. This means that PSMA is a good biomarker or target for imaging, diagnostic, prognostic purposes. However, as PSMA is also expressed in other tissues, both normal and malignant, there are difficulties in successfully imaging prostate cancer.
A radiolabeled compound may be used as a radiopharmaceutical or a radioimaging agent if it can bind sufficiently to the desired site and a radionuclide can also be delivered to the same site for imaging or therapeutic purposes.
Compounds or ligands containing urea-based motifs, such as the following glutamic acid substituted ureas, are known to bind with good affinity to the catalytic site of PSMA.
Although compounds containing this or similar motifs have been synthesized, problems have been observed with their stability or binding behavior in vivo. In order for a compound to be useful for radiographic or radiotherapy, the compound and the resulting complex comprising the radionuclide must be stable in vivo. One of the known problems associated with radiolabeled compounds is that the complex formed with the radionuclide is not sufficiently strong and the radionuclide "bleeds" from the complex and is not delivered to the intended site. Other problems caused by radionuclide bleedout include the diffusion of the radionuclide to unwanted sites. This may result in damage to healthy tissue due to the activity of the radionuclide. Furthermore, the diffusion of radionuclides leads to poor quality images because the contrast between the true binding sites (indicating the location of the tumor) and sites with unwanted radionuclides is reduced.
Other problems associated with radiolabeled compounds include the possibility of radiolysis, where the radioisotope itself can lead to destruction of the compound and subsequent diffusion of the radionuclide. Spontaneous decay of the radionuclide causes radiolysis to occur, and the energy released results in bond cleavage in the ligand and destruction of the complex. Radiolysis also causes the radionuclide to diffuse to unwanted locations, further exacerbating the above problem.
Since the compound is to be administered to a human in need thereof, the compound must also be non-toxic to the subject itself. Another problem associated with the use of radiolabeled compounds for diagnosis, imaging and therapy is the problem of binding affinity. The binding affinity to the target, i.e. PSMA in this case, is low and the complex may not achieve binding and be excreted or may show only limited binding. This results in a reduction in overall efficacy when the complex is immediately excreted. However, where the complex exhibits limited excretion and limited binding, the complex may diffuse throughout the subject and cause the aforementioned adverse effects. Furthermore, limited binding of the complex will likely reduce the time available for acceptable imaging or treatment of tumors.
There is a need for a class of compounds that can provide the desired binding affinity to prostate cancer-associated tumors and also have the ability to provide the necessary imaging properties. It is also desirable that these compounds be sufficiently stable and not decompose during use.
Disclosure of Invention
The present invention relates to novel compounds that exhibit improved binding affinity for PSMA. The present inventors have found that the use of an amino acid substituted urea bound to a macrocyclic sarcophagine (sarcophagine) through a specific linker provides a compound that binds to PSMA and, when complexed with a radionuclide, provides good/improved imaging performance.
In one aspect, the present invention provides a compound of formula (I) or a salt, complex, isomer, solvate or prodrug thereof:
wherein:
x is selected from H, OH, halogen, cyano, NO2、NH2Optionally substituted C1-C12Alkyl, optionally substituted amino, optionally substituted amide and optionally substituted aryl;
y is optionally substituted C1-C12Alkylene, wherein one or more methylene groups in the alkylene may be further optionally substituted with a group selected from amide, carbonyl, urea and thiourea;
m is 0,1 or 2;
n is 0,1 or 2.
In one embodiment, the compound, or a salt, complex, isomer, solvate or prodrug thereof, has the formula:
in another embodiment, the compound, or a salt, complex, isomer, solvate or prodrug thereof, has the formula:
in another embodiment, the compound, or a salt, complex, isomer, solvate or prodrug thereof, has the formula:
in another aspect, the invention provides a composition comprising a compound according to the preceding aspect and a pharmaceutically acceptable excipient.
In another aspect, the present invention provides an aqueous composition for parenteral administration comprising a compound of the above aspect, wherein the composition further comprises: ethanol, gentisic acid or a salt thereof, and sodium chloride.
In another aspect, the present invention provides a method for the treatment or prevention of a disorder in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound according to the above aspect or a composition according to the above aspect.
Drawings
FIG. 1: at 30 minutes, 2 hours and 22 hours64PET imaging of Cu-Sar-PSMA treated NSG mice carrying LNCaPs.
FIG. 2: shown in NSG mice carrying LNCaPs64Graph of the biodistribution of Cu-Sar-PSMA at 22 hours versus blood level (right).
FIG. 3: at 1 and 6 hours with64PET imaging of Cu-Sar-PSMA treated NSG mice carrying LNCaPs.
FIG. 4: display device64The biodistribution of Cu-Sar-PSMA in LNCaP carrying NSG mice at 1 and 6 hours.
FIG. 5: a graph showing the biodistribution of various radiolabeled complexes in LNCaPs xenograft mice, expressed as tumors at 1 hour: the proportion of uptake in the kidney.
FIG. 6: shown in LNCaPs xenografted mice64Cu-Sar-PSMA and68graph of preclinical biodistribution of Ga-labeled complexes, expressed as tumor at 1 hour: the proportion of uptake in the kidney.
FIG. 7: a graph showing the biodistribution of various radiolabeled complexes in LNCaPs xenograft mice, expressed as the ratio of the total weight of the drug in the tumor: the proportion of uptake in the kidney.
FIG. 8: structure of PSMA ligand targets of the prior art.
FIG. 9: with UV detection at 220nm64HPLC chromatograms of Cu-Sar-PSMA (RT: 12.43 min.) compared with natCu-Sar-PSMA (RT: 12.38 min.).
FIG. 10:64Cu-CoSar(PSMA)2radio-HPLC chromatogram of (RT: 13.9 min).
FIG. 11: CoSar (PSMA)2Analytical HPLC chromatogram of (RT: 10.3 min), UV detection at 220 nm.
Detailed Description
As described and shown herein, the inventors have discovered that compounds comprising an amino acid substituted urea attached to the sarcophagus cage via a linker group can bind to PSMA. Without wishing to be bound by theory, it is believed that the combination of the amino acid-urea fragment, linker and sarcophagus cage is believed to provide the advantages observed and discussed below.
The complexes described herein are radiolabeled with a radionuclide or radioisotope that undergoes spontaneous decay, with the by-products of such decay being detected by various means, such as Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT). The quality of the images obtained and the confidence in subsequent diagnosis based on these images depends on the ability of the radiolabeled complex to specifically bind to prostate cancer sites.
As used herein, the term "sarcophagus" refers to a nitrogen-containing macrocyclic ligand having the formula 3,6,10,13,16, 19-hexaazabicyclo [6.6.0] eicosane.
The term "optionally substituted" as used throughout the specification means that the group may or may not be further substituted or fused (to form a fused polycyclic ring system) with one or more non-hydrogen substituent groups. In certain embodiments, the substituents are one or more independently selected from halogen, ═ O, ═ S, -CN, -NO2、-CF3、-OCF3Alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkenyl, heterocycloalkylalkenyl, arylalkenyl, heteroarylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, arylheteroalkyl, heteroarylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycycloalkyl, alkoxyheterocycloalkyl, alkoxyaryl, alkoxyheteroaryl, alkoxycarbonyl, alkylaminocarbonyl, alkenyloxy, alkynyloxy, cycloalkoxy, cycloalkenyloxy, heterocycloalkoxy, heterocycloalkenyloxy, aryloxy, phenoxy, benzyloxy, heteroaryloxy, arylalkoxy, amino, alkylamino, acylamino, heteroaryloxy, heteroarylalkoxy, alkoxyalkoxy, alkoxyheteroaryl, alkoxyalkoxy, alkoxycarbonyl, alkylaminocarbonyl, alkenyloxy, alkoxyalkoxy, cycloalkoxy, cycloalkenyloxy, heterocycloalkyloxy, aryloxy, benzyloxy, heteroaryloxy, arylamin,Aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, alkylsulfinyl, arylsulfinyl, aminosulfinylaminoalkyl, -C (═ O) OH, -C (═ O) Ra、-C(=O)ORa、C(=O)NRaRb、C(=NOH)Ra、C(=NRa)NRbRc、NRaRb、NRaC(=O)Rb、NRaC(=O)ORb、NRaC(=O)NRbRc、NRaC(=NRb)NRcRd、NRaSO2Rb、-SRa、SO2NRaRb、-ORa、OC(=O)NRaRb、OC(=O)RaAnd acyl, wherein, Ra、Rb、RcAnd RdEach independently selected from H, C1-C12Alkyl radical, C1-C12Haloalkyl, C2-C12Alkenyl radical, C2-C12Alkynyl, C2-C10Heteroalkyl group, C3-C12Cycloalkyl radical, C3-C12Cycloalkenyl radical, C2-C12Heterocycloalkyl radical, C2-C12Heterocycloalkenyl, C6-C18Aryl radical, C1-C18Heteroaryl and acyl, or Ra、Rb、RcAnd RdTogether with the atoms to which they are attached, form a heterocyclic ring system having from 3 to 12 ring atoms.
In some embodiments, each optional substituent is independently selected from: halogen, ═ O, ═ S, -CN, -NO2、-CF3、-OCF3Alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkoxyheteroaryl, alkenyloxy, alkynyloxy, cycloalkoxy, cycloalkenyloxy, heterocycloalkaneAryloxy, heterocycloalkenyloxy, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, arylalkoxy, amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, aminoalkyl, -COOH, -SH and acyl.
Examples of particularly suitable optional substituents include F, Cl, Br, I, CH3、CH2CH3、OH、OCH3、CF3、OCF3、NO2、NH2、COOH、COOCH3And CN.
"alkenyl" as a group or part of a group means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond, which may be straight or branched, preferably having from 2 to 12 carbon atoms, more preferably from 2 to 10 carbon atoms, and most preferably from 2 to 6 carbon atoms in the normal chain. The group may contain multiple double bonds in the normal chain, and each orientation is independently E or Z. Exemplary alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, and nonenyl.
Unless otherwise indicated, "alkyl" as a group or part of a group refers to a straight or branched chain aliphatic hydrocarbon group, preferably C1-C12Alkyl, more preferably C1-C10Alkyl, most preferably C1-C6. Suitable straight and branched chains C1-C6Examples of alkyl substituents include methyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl, tert-butyl, hexyl and the like.
"alkynyl" as a group or part of a group refers to an aliphatic hydrocarbon group containing a carbon-carbon triple bond, which may be straight or branched, preferably having from 2 to 12 carbon atoms, more preferably from 2 to 10 carbon atoms, and still more preferably from 2 to 6 carbon atoms in its normal chain. Exemplary structures include, but are not limited to, ethynyl and propynyl.
"aryl" as a group or part of a group means: (i) optionally substituted monocyclic or fused polycyclic, aromatic carbocycle (having a ring structure with all ring atoms being carbon), each ring preferably having 5 to 12 atomsExamples of aryl groups include phenyl, naphthyl, and the like; (ii) optionally substituted partially saturated bicyclic aromatic carbon ring moiety wherein phenyl and C5-7Cycloalkyl or C5-7The cycloalkenyl groups are fused together to form a cyclic structure, such as tetrahydronaphthyl, indenyl, or indanyl. Typically, aryl is C6-C18And (4) an aryl group.
Unless otherwise indicated, "cycloalkyl" refers to a saturated monocyclic or fused or spirocyclic polycyclic carbocyclic ring, preferably containing from 3 to 9 carbons per ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. It includes monocyclic systems (e.g., cyclopropyl and cyclohexyl), bicyclic systems (e.g., decalin), and polycyclic systems (e.g., adamantane). Cycloalkyl is usually C3-C9A cycloalkyl group.
"halogen" represents chlorine, fluorine, bromine or iodine.
"Heteroalkyl" means a straight or branched chain alkyl group preferably having 2 to 12 carbons, more preferably 2 to 6 carbons in the chain, in which one or more carbon atoms (and any associated hydrogen atoms) are each independently substituted with a heteroatom group selected from S, O, P and NR ', wherein R' is selected from H, optionally substituted C1-C12Alkyl, optionally substituted C3-C12Cycloalkyl, optionally substituted C6-C18Aryl and optionally substituted C1-C18A heteroaryl group. Exemplary heteroalkyl groups include alkyl ethers, secondary and tertiary alkyl amines, amides, alkyl sulfides, and the like. Examples of heteroalkyl groups also include: hydroxy radical C1-C6Alkyl radical, C1-C6Alkoxy radical C1-C6Alkyl, amino C1-C6Alkyl radical, C1-C6Alkylamino radical C1-C6Alkyl and di (C)1-C6Alkyl) amino C1-C6An alkyl group.
"heteroaryl" alone or as part of a group refers to a group containing an aromatic ring (preferably a 5 or 6 membered aromatic ring) wherein one or more heteroatoms as ring atoms are present in the aromatic ring and the remaining ring atoms are carbon atoms. Suitable heteroatoms include nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include thiophene, benzothiophene,benzofuran, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho [2,3-b ]]Thiophene, furan, isoindoline, xanthine, phenoxathiin, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, tetrazole, indole, isoindole, 1H-indazole, purine, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, cinnoline, carbazole, phenanthridine, acridine, phenazine, thiazole, isothiazole, phenothiazine, oxazole, isoxazole, furazan, phenoxazine, 2-, 3-or 4-pyridyl, 2-, 3-, 4-, 5-or 8-quinolyl, 1-, 3-, 4-or 5-isoquinolyl, 1-, 2-or 3-indolyl, and 2-or 3-thienyl. Heteroaryl is usually C1-C18A heteroaryl group.
As used herein, the term "C1-C12Alkylene "refers to a divalent straight or branched chain aliphatic hydrocarbon group wherein the group has from 1 to 12 carbon atoms in the chain.
In one embodiment, X is optionally substituted C1-C12An alkyl group.
In one embodiment, X is C1-C12An alkyl group.
In one embodiment, X is optionally substituted C1-C3An alkyl group.
In one embodiment, X is C1-C3An alkyl group.
In one embodiment, X is methyl.
In one embodiment, X is CH3。
In one embodiment, X is optionally substituted amino, e.g., -NCH3。
In one embodiment, X is amino.
In one embodiment, X is an optionally substituted amide. As used herein, the term "amide" refers to a functional group consisting of a carbonyl group attached to a nitrogen atom. Thus, the term "optionally substituted amide" refers to an amide functional group with further substitution.
in one embodiment, Y is a substituted alkylene.
In one embodiment, Y is unsubstituted alkylene.
In one embodiment, Y is CH2。
In one embodiment, Y is carbonyl.
In one embodiment, Y is substituted C1-C12Alkylene groups in which one or more of the methylene groups is further substituted with an amide group, for example,
in one embodiment, n is 1.
In one embodiment, n is 2.
In one embodiment, n is 0.
In one embodiment, m is 1.
In one embodiment, m is 2.
In one embodiment, m is 0.
In one embodiment, the invention provides a compound of the formula:
in another embodiment, the invention provides a compound of the formula:
wherein,
the two phenylalanine residues are D-Phe, giving rise to the MeCOSar-D-Phe-D-Phe-AOC-Lys-urea-Glu ligand. The inventors have found that the use of phenylalanine residues for specific D-stereochemistry may result in compounds with improved metabolic stability. In addition, the inventors have also determined that the use of two D-Phe residues in the ligand may increase the hydrophobicity of the compound and the potential pi-pi interaction of the ligand with the binding pocket of the target enzyme.
In another embodiment, the invention provides a compound of the formula:
in another embodiment, the invention provides a compound of the formula:
the compounds contain two linkers and two ureido groups that bind to PSMA. Without wishing to be bound by theory, it appears that this compound with two urea motifs may show a further improved binding affinity to PSMA. It is also believed that such a double derivative, i.e., a compound having two linkers and two urea motifs, can provide a better signal-to-noise ratio when used for imaging purposes and compared to a corresponding single compound having a single linker and a urea motif. The dual compounds may also show further improvement in clearance from the kidney when administered. When comparing mono-and bis-compounds, this may be due to differences in overall charge and charge separation and distribution.
In another embodiment, the invention provides a compound of the formula:
in another embodiment, the invention provides a compound of the formula:
in another embodiment, the invention provides a compound of the formula:
in one embodiment, the compound is coordinated to a metal ion.
In one embodiment, the metal ion is Cu, Tc, Gd, Ga, In, Co, Re, Fe, Au, Mg, Ca, Ag, Rh, Pt, Bi, Cr, W, Ni, V, Ir, Zn, Cd, Mn, Ru, Pd, Hg, Ti, Lu, Sc, Zr, Pb, Ac, and Y.
In one embodiment, the metal ion is a radionuclide.
In some embodiments, the metal In the metal ion is a radionuclide selected from the group consisting of Cu, Tc, Ga, Co, In, Fe, and Ti. The compounds of the invention have been found to be particularly useful for binding copper ions. In some embodiments, the metal in the metal ion is selected from the group consisting of60Cu、61Cu、62Cu、64Cu and67radionuclides of the group consisting of Cu. In some embodiments, the metal in the metal ion is60And (3) Cu. In some embodiments, the metal in the metal ion is61And (3) Cu. In some embodiments, the metal in the metal ion is62And (3) Cu. In some embodiments, the metal in the metal ion is64And (3) Cu. In some embodiments, the metal in the metal ion is67Cu。
The compounds of formula (I) comprise a sarcophagous macrocyclic ligand and a Lys-urea-Glu moiety targeting PSMA. The compound also comprises an intermediate portion connecting the sarcophagus and the PSMA targeting moiety. In formula (I), these include a propyl linkage in combination with two amide groups, two phenylalanine residues, and one aminocaprylic Acid (AOC) group. The propyl linker, phenylalanine residue and aminocaprylic acid group together act as a spacer to separate the sarcophagus and PSMA targeting moiety. A degree of separation between the sarcophagus and PSMA targeting moiety is desirable to ensure that the activities of the two groups do not interfere with each other, however, it is important that the two groups are not spaced too far apart in order to deliver the radionuclide complex to the site of action defined by the PSMA targeting moiety in the presence of the bound radionuclide in the sarcophagus. PSMA targeting moieties comprise a Lys-urea-Glu moietyIt has three carboxyl functional groups that provide the overall negative charge and contribute to the zinc binding domain. The amino octanoic acid group adjacent to the PSMA targeting moiety is designed to provide a length of aboutTo separate the charge between the PSMA targeting moiety and the rest of the molecule. The two D-phenylalanine residues are hydrophobic in nature and allow pi-pi binding interaction with the active site. These residues also contribute to the metabolic stability of the compound. The propenyl group located between the two amide functions also serves to provide the necessary distance between the macrocyclic ligand (chelating the positively charged Cu ions) and the PSMA targeting moiety. The inventors have found that the compounds according to the invention comprise various fragments (i.e. macrocyclic ligands, linkers and PSMA targeting moieties) which together provide a PSMA binding ligand with the requisite stability and binding affinity.
In one embodiment, the present invention provides a composition comprising a compound as described above and a pharmaceutically acceptable excipient.
In another aspect, the present invention provides a method of treating or preventing a disorder in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound described above or a composition thereof.
In one embodiment, the disorder is cancer.
In one embodiment, the disease is breast cancer, colon cancer, lung cancer, ovarian cancer, prostate cancer, head and/or neck cancer, or kidney, stomach, pancreatic cancer, brain cancer, hematologic malignancies such as lymphoma or leukemia.
In one embodiment, the disorder is prostate cancer.
In another aspect, the invention provides a method of radioimaging a subject, the method comprising administering an effective amount of a compound or composition thereof as described above.
Ideally, the radiopharmaceutical should remain in the intended target location, but not in any other location, and clear any unbound radiopharmaceutical from the circulatory system. This will then allow images with sufficient contrast to be obtained, which in turn allows more accurate analysis and diagnosis. For this reason, the radiolabeled complex should have physical and chemical properties in which the bound complex remains bound at the desired site for a time sufficient to allow the necessary imaging, but any unbound complex should be removed from the subject to prevent any background radiation caused by the unbound complex, interfering with and reducing the contrast of the acquired image.
The compounds of the invention show a more favorable distribution profile in vivo. FIGS. 2 and 4 show administration to tumor-bearing mice64Cu-Sar-PSMA leads to localization of the compound in the tumor rather than in any major organ or blood. Minimizing binding of the radiolabeled complex to other tissues can reduce damage to healthy tissues. This complex showed relatively little accumulation in the bloodstream, which also showed high binding affinity of Sar-PSMA complex to PSMA-expressing tumors.
In contrast to other known radiolabelled complexes (see FIG. 5), for example68Ga-PSMA-617、177Lu-PSMA-I&T and68Ga-DOTAGA-ffk(PSMA),64the Cu-Sar-PSMA complex showed more tumor uptake. In addition, when considering renal uptake (meaning excretion of the compound), compared to other compounds that show similar binding to the tumor site,64Cu-Sar-PSMA showed significantly less renal uptake. FIG. 6 shows64Cu-Sar-PSMA complexes and a variety of68A similar comparison between Ga complexes shows that use is made of64Cu radionuclides may also be used as well68The Ga radionuclide complexes bind as well or are used in comparison with68Complexes of Ga radionuclides bind better to tumors. In addition, and have68Compared with the complex of the Ga radioactive nuclide,64the Cu-Sar-PSMA complex showed less renal uptake.
Subsequently, the present inventors found that Sar-PSMA ligands and64the Cu radionuclide shows better affinity to the tumor site andbetter clearance from the kidney after administration. These advantages allow better imaging results to be obtained, i.e. higher affinity to the tumor site provides an image with better contrast, since the radionuclide is mainly located at the target site and unbound ligands are better removed from the circulation, thereby reducing background accumulation. This may then improve the diagnosis of tumours such as prostate cancer. The increased affinity for the tumor binding site also indicates that the radionuclide has less diffusion to other tissues, thereby improving the quality of the images obtained. Furthermore, minimizing the diffusion of the radionuclide to non-tumor sites means that less radiolabeled complex is required for administration and any deleterious effects of the radioactive complex are localized so that healthy tissue is not affected.
The inventors have found that the compounds of the present invention can be used as diagnostic and therapeutic compounds. The diagnostic method allows the same compound to be used for diagnosis and treatment of indications, with advantages compared to the diagnosis with one compound and the treatment with another compound. Overall, this may improve the efficiency of diagnosis and treatment of a particular disease. This is in contrast to conventional methods, where ligands with specific isotopes may be suitable for diagnosing disease, but the same combination of ligand and isotope may not be suitable for treating disease. This then requires modification of the ligand, the isotope, or both the ligand and the isotope in order to treat the disease.
FIG. 7 shows the accumulation of radiolabeled complex in the tumor and kidney over time.
In application of64In the case of the Cu-Sar-PSMA complex, the ratio of tumor-localized complex to tumor-localized complex increased up to 24 hours. FIG. 7 shows the tumor sites after 1 hour64The absorption of the Cu-Sar-PSMA complex was greater than that of the other radiolabeled complexes, indicating that64The absorption rate of the Cu-Sar-PSMA complex is faster than that of the other comparative complexes. Furthermore, the ratio of complex in the tumor to the kidney did not increase until 24 hours, indicating that the complex has a favourable binding affinity for the tumor. This has the advantage that the complex remainsLonger time integration allows imaging of the object during this time period, which results in better quality and higher contrast images. This then allows a more accurate diagnosis of the disease.
64The Cu-Sar-PSMA complex showed higher binding affinity than other radiolabeled complexes, which also suggests that the same complex may be used therapeutically. Since the therapeutic properties of the complex depend on the delivery of the radionuclide to the target site, i.e. the tumor, good specificity and affinity for the tumor site is essential. This allows the radionuclide to deliver the radiotherapy effect to the desired site and prevent damage to other tissues. Furthermore, the ability of the radiolabeled complex to remain bound to the target site allows for the delivery of a prolonged therapeutic effect, which increases the efficiency of the therapeutic approach.
The inventors have now shown that it is possible to,64the Cu-Sar-PSMA radiolabeled complex has sufficient binding specificity and affinity for the target PSMA site such that administration of a therapeutically effective amount of the radiolabeled complex is useful for treating prostate cancer.
The inventors have now also shown that Sar-PSMA complexes radiolabeled with copper isotopes are useful for diagnostic and therapeutic purposes. For example,64the Cu-Sar-PSMA radiolabeled complexes may be used for diagnostic and therapeutic purposes.67The Cu-Sar-PSMA radiolabeled complexes may also be used for diagnostic and therapeutic purposes.
The term "pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the above compounds, including pharmaceutically acceptable acid addition salts and base addition salts. Suitable pharmaceutically acceptable acid addition salts of the compounds of formula (I) may be prepared from inorganic or organic acids. Examples of such inorganic acids are hydrochloric acid, sulfuric acid and phosphoric acid. Suitable organic acids may be selected from aliphatic, alicyclic, aromatic, heterocyclic carboxylic and sulfonic organic acids, such as formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, fumaric, maleic, alkyl sulfonic and aryl sulfonic acids. Additional information on pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences,19th Edition, mack publishing co., Easton, PA 1995. In the case of solid reagents, it will be understood by those skilled in the art that the compounds, reagents and salts of the invention may exist in different crystalline or polymorphic forms, all of which are intended to be within the scope of the invention and the specific chemical structure.
The term "therapeutically effective amount" or "effective amount" is an amount sufficient to produce a beneficial or desired clinical result. An effective amount may be administered in one or more administrations. An effective amount is generally sufficient to alleviate, ameliorate, stabilize, reverse, slow or delay the progression of the disease state. An effective amount of the radiographic image is generally sufficient to identify the radionuclide in the subject.
Monitoring the location of the radiolabeled material of the subject will typically provide the analyst with information about the location of the radiolabeled material and thus any material targeted by the molecular recognition moiety (e.g., cancerous tissue). The effective amount of a compound of the invention will depend on many factors and will necessarily involve a balance between the amount of radioactivity required to achieve the desired radiographic effect and the general benefit of avoiding exposure of the subject (or its tissues or organs) to any unnecessary levels of harmful radiation.
The therapeutic methods of the invention comprise administering a compound of formula (I) complexed with a radionuclide. The compounds of formula (I) are capable of delivering a radionuclide to a desired location in the body where its mode of action is desired.
The therapeutically effective amount can be readily determined by the attending physician using conventional techniques and by observing results obtained under analogous circumstances. In determining a therapeutically effective amount, a number of factors are considered, including but not limited to the species, size, age, and general health of the animal, the particular condition involved, the severity of the condition, the patient's response to treatment, the particular radiolabeled compound administered, the mode of administration, the bioavailability of the formulation, the selected dosage regimen, the use of other drugs, and other relevant circumstances.
In addition, the treatment regimen will typically involve multiple cycles of radiation therapy that continue until the condition is alleviated. Again, the optimal number of cycles and the interval between each treatment cycle will depend on a number of factors, such as the severity of the condition being treated, the health of the subject being treated (or its lack) and its response to radiation therapy. In general, optimal dosages and optimal treatment regimens can be readily determined by those skilled in the art using well known techniques.
Where compounds of the invention are used, they may be administered in any form or manner that makes the compounds useful for the desired application (imaging or radiotherapy). One skilled in the art of preparing formulations of this type can readily select the appropriate form and mode of administration, depending on the particular characteristics of the compound selected, the condition being treated, the stage of the condition being treated, and other relevant circumstances. We provide the reader with information on Remington's Pharmaceutical Sciences,19thedition, Mack Publishing Co. (1995).
The compounds of the present invention may be administered alone or in combination with a pharmaceutically acceptable carrier, diluent or excipient in the form of a pharmaceutical composition. Although the compounds of the present invention are effective per se, they are generally formulated and administered in the form of their pharmaceutically acceptable salts, since these forms are generally more stable, more readily crystallized and have increased solubility.
However, the compounds are generally used in the form of pharmaceutical compositions, which are formulated according to the desired mode of administration. The compositions are prepared in a manner well known in the art.
In other embodiments, the present invention provides a pharmaceutical package or kit comprising one or more containers containing one or more of the ingredients of the pharmaceutical compositions of the present invention. In such a package or kit, at least one container with a unit dose of medicament may be found. Conveniently, in the kit, a single dose may be provided in a sterile vial so that the clinician can use the vial directly, wherein the vial will have the desired amount and concentration of the compound and the radionucleotide, which may be mixed prior to use. Associated with such containers may be various written materials, such as instructions for use, or a notice in the form of a government agency regulating the manufacture, use or sale of a pharmaceutical, imaging or biological product, which notice reflects approval by the agency of manufacture, use or sale for human administration.
The compounds of the invention may be used or administered with one or more additional drugs that are anti-cancer drugs and/or methods for treating such disorders/diseases (e.g., surgery, radiation therapy). The components may be administered in the same formulation or in separate formulations. If administered in separate formulations, the compounds of the invention may be administered sequentially or simultaneously with other drugs.
In addition to being able to be administered in combination with one or more other drugs including anticancer drugs, the compounds of the present invention may also be used in combination therapy. After this procedure, the compounds are usually administered in combination with each other. Thus, one or more compounds of the invention may be administered simultaneously (as a combined preparation) or sequentially to achieve the desired effect. This is particularly desirable when the therapeutic properties of each compound differ such that the combined action of the two drugs provides an improved therapeutic effect.
Pharmaceutical compositions of the invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include: water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (e.g., olive oil), and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating material, such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. Prevention of the action of microorganisms can be ensured by including various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
If desired, and for more efficient distribution, the compounds can be incorporated into slow release or targeted delivery systems, such as polymer matrices, liposomes, and microspheres.
The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
In one embodiment, the present invention provides an aqueous composition of a compound of formula (I):
wherein: x is selected from H, OH, halogen, cyano, NO2、NH2Optionally substituted C1-C12Alkyl, optionally substituted amino, optionally substituted amide and optionally substituted aryl;
y is optionally substituted C1-C12Alkylene, wherein one or more methylene groups in the alkylene are optionally substituted with a group selected from amide, carbonyl, urea, and thiourea;
m is 0,1 or 2;
n is 0,1 or 2;
wherein the compound of formula (I) is complexed with Cu ions;
wherein the composition further comprises: ethanol, gentisic acid or a salt thereof, and sodium chloride.
The present inventors have found that the use of gentisic acid and ethanol in the composition of the compound of formula (I) with complexed Cu ions may help to prevent or minimise radiolysis of the radiolabelled complex.
In the above examples, the compositions of the present invention comprise ethanol as a component. The ethanol used in the composition may be anhydrous ethanol. Alternatively, the ethanol used in the composition may not have undergone a drying process and may be hydrated. The ethanol is preferably pharmaceutical grade ethanol. The presence of ethanol in the composition may help to prevent radiolysis of the radiolabeled complex of formula (I).
In the above examples, the compositions of the present invention also included sodium chloride as a component. The sodium chloride in the formulation of the present invention may be provided in the form of a salt solution. The salt solution is defined as an aqueous solution of sodium chloride. For example, physiological saline is defined as an aqueous solution of sodium chloride at a concentration of 0.9% (w/v). In one embodiment of the invention, the sodium chloride of the formulation is provided by a saline solution.
In the above embodiments, the composition of the present invention comprises gentisic acid or a pharmaceutically acceptable salt and/or hydrate thereof as a component. Gentisic acid is also known as 2, 5-dihydroxybenzoic acid, 5-hydroxy salicylic acid or hydroquinone carboxylic acid. Salts of gentisic acid may include sodium salts and sodium salt hydrates. Where relevant, any reference to gentisic acid may include a reference to a salt thereof. The present inventors have determined that gentisic acid or a salt thereof in the composition of the invention may help to prevent or minimise radiolysis of the radiolabelled complex of formula (I).
Oral solid dosage forms include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia, c) humectants, such as glycerol, d) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate, e) solution retarders, such as paraffin, f) absorption accelerators, such as quaternary ammonium compounds, g) wetting agents, such as cetyl alcohol and glycerol monostearate, h) absorbents, such as kaolin and bentonite, and i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. For capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
Solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and may also have a composition that they release the active ingredient(s) only, or preferably, in certain parts of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that may be used include polymeric substances and waxes.
If desired and for more efficient distribution, the compounds can be incorporated into slow release or targeted delivery systems, such as polymer matrices, liposomes, and microspheres.
The active compounds can also be in microencapsulated form, if appropriate with one or more of the abovementioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and esters of fatty acid sorbitan, and mixtures thereof.
In addition to inert diluents, oral compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
As noted above, the compounds of the examples are useful for treating and/or detecting proliferative diseases. Examples of such cell proliferative diseases or disorders include cancer (including any metastatic cancer), psoriasis and smooth muscle cell proliferative diseases, such as restenosis. The compounds of the invention are particularly useful for the treatment and/or detection of tumors, such as breast, colon, lung, ovarian, prostate, head and/or neck cancer, or renal, gastric, pancreatic and brain cancer, as well as hematological malignancies, such as lymphomas and leukemias. In addition, the compounds of the invention are useful for the treatment and/or detection of proliferative diseases that are refractory to the treatment and/or detection of other anticancer agents. For the treatment and/or detection of hyperproliferative diseases, such as leukemia, psoriasis and restenosis. In other embodiments, the compounds of the invention are useful for treating and/or detecting pre-cancerous conditions or hyperplasia, including familial adenomatous polyposis, adenomatous polyposis coli, myeloid dysplasia, endometrial hyperplasia complications, cervical dysplasia, vaginal intraepithelial hyperplasia, benign hyperplasia, laryngeal papilloma, actinic and solar keratosis, seborrheic keratosis, and acanthoma angulatus.
Synthesis of Compounds of the invention
The reagents of the various examples can be prepared using reaction schemes and synthetic schemes described below, using techniques available in the art, using readily available starting materials. The preparation of specific compounds of the examples is described in detail in the following examples, but the skilled person will recognize that the chemical reactions described may be readily adapted to prepare many other reagents of the various examples. For example, the synthesis of non-exemplified compounds can be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriate protection of interfering groups, by alteration to other suitable reagents known in the art, or by routine modification of reaction conditions. A list of suitable protecting Groups in Organic Synthesis may be found in T.W.Greene's Protective Groups in Organic Synthesis,3rdEdition,John Wiley&Sons, 1991. Alternatively, other reactions disclosed herein or known in the art will be recognized as having other reagents for making the various embodimentsSuitability of the compound. Reagents for synthesizing the compounds may be obtained or prepared according to techniques known in the art.
Example 1
Synthesis of Sar-PSMA
MeCOSar-D-Phe-Aoc-Lys-urea-Glu ligand 1, wherein Aoc ═ 8-aminocaprylic acid (i.e., Sar-PSMA) was prepared by solid phase peptide synthesis. The glutamic acid-urea-lysine binding motif is synthesized by reacting imidazole-activated and protected glutamic acid with protected L-lysine immobilized on Wang resin. The peptide linker was attached to the epsilon-amine of lysine by solid phase peptide synthesis using standard Fmoc protocol. By reacting (tBoc)4-5Coupling of the chelator is carried out by reaction of MeCOSar with a linker-urea protected on the side chain on a solid support. Sar-PSMA was cleaved from the resin and simultaneously deprotected (TFA/TIPS/H20).
64Radiolabeling of Sar-PSMA with Cu
In aqueous solution (0.1 MNH) at room temperature4OAc, pH8, 1-10nmolSar Sar-PSMA) in a pharmaceutical composition64CuIISar-PS MA ligand 1 was radiolabeled. 64Cu-Sar-PSMA was obtained in > 94% yield (n.d.c.) and > 97% radiochemical yield (7.95-21.9 GBq/. mu.mol) from solid phase cartridges (Phenomenex Strata-X RP60 mg/mL).
Synthesis of activated Glu intermediate 3
The literature: duspara, P.A.; islam, m.s.; lough, a.j.; batey, R.A., Synthesis and resolution of N-alkyl carboxylic acids, displacement of N-methyl carboxylic acids as a methyl isocyanate equivalent.J. Org Chem 2012,77(22), 10362-8.
To a solution containing L-bis (tBu) Glu
To a flask of HCl2(3.56g, 12.04mmol, 1.0eq) and carbonyldiimidazole (2.15g, 13.24mmol, 1.1eq) was added 1: 5 DMF/MeCN mixture (50 mL). The reaction was stirred at rt overnight. After stirring, the solvent was removed in vacuo and the remaining crude mixture was dissolved and purified by flash chromatography (mobile phase: 7: 3: 1 white spirit/chloroform/methanol, Rf: -0.24, 30: 1 silica/crude mass ratio) to give the product as a white semi-crystalline powder (2.25g, 52.9% yield).
Fmoc-Lys (DDiv) -OH loading in Wang resin
To a 50mL fluoroalcon tube containing Wang resin (1.028g, 1.15mmol/g, 1.18mmol) was added preactivated in DMF
A mixture of Fmoc-Lys (DDiv) -OH (2.038g, 3.55mmol, 3.0eq), HCTU (1.33g, 3.5mmol, 2.96eq), DIPEA (1.24mL, 7.09mmol, 6eq), DMAP (43.3mg, 0.355mmol, 0.3 eq). The resin was allowed to react by placing it on a shaker for 2 hours. Acetic anhydride (223 μ L, 2.36mmol, 2eq) and pyridine (190 μ L, 2.36mmol, 2eq) were then added to the reaction mixture to cover the remaining functional groups of the resin and stirred for 30 minutes. The resin was then filtered and washed with DMF X3, DCM X3, MeOH X2 and Et2Ox 2 was washed, dried, and weighed to determine the final resin loading (0.759 mmol/g). Resin loading was determined as follows:
synthesis of resin-protected KuE4
The Sar-PSMA ligand was synthesized from the KuE motif on the resin under standard Fmoc solid phase peptide synthesis conditions.
General Fmoc deprotection protocol
Resin bound peptide 4 was treated with 20% piperidine in DMF for 5 min three times. The resin was then washed sequentially with DMF X3 and DCM X3.
TNBSA test for confirmation of coupling/deprotection reactions
Each coupling/deprotection step was qualitatively tested using the TNBSA (trinitrobenzene sulfonic acid) test. A small portion of the resin (about 20 beads) was placed in an Eppendorf tube. TNBSA (10 μ L of 5% DMF solution) and DIPEA (10 μ L of 5% DMF solution) were added, and the mixture was stirred for 2 min. If no color change of the resin is observed, the test indicates the absence of primary amine, while the orange color of the resin indicates the presence of free primary amine.
After deprotection, activated Glu intermediate 3(0.95g, 2.69mmol, 2.0eq) and DIPEA (240 μ l, 1.38mmol, 1.0eq) in DMF (5mL) were added to the resin. The resin was stirred manually for 24 h and washed with DMF X3 and DCM X3. After confirmation and testing of cleavage/MS by TNBSA coupling, the DDiv group was deprotected by treatment with DMF x 3 containing 2% hydrazine hydrate to give 5.
General protocol for Fmoc-amino acid coupling to resin
Fmoc amino acids (3eq) were activated using a DMF solution containing HCTU (0.96 eq relative to AA) and DIPEA (2eq relative to AA). After 5 minutes, the solution was added to the resin and stirred intermittently. After 20 min, the resin was filtered and washed sequentially with DMF × 1, DCM × 3 and DMF × 3 to give 6.
Coupling of MeCOSar to the PSMA ligand on the resin yielded 7
BocMeCosar (0.464g, 0.5mmol, 1.2eq) was activated using a DMF solution containing HCTU (0.207g), HOBt (67.6mg) and DIPEA (174. mu.L). After 5 minutes, the solution was added to resin 6(0.4mmol) and stirred intermittently. After 24 h, the resin was filtered and washed sequentially with DMF X1, DCM X3 and DMF X3.
Resin cleavage protocol to yield 1
Resin 7 was washed several times with DCM and then transferred to a 50mL Falcon tube. 95:2.5:2.5TFA/TIPS/H2O (15mL) was added to the resin and stirred at room temperature for 2 h. The resin was filtered and washed twice with 3ml of LTFA. The filtrate was collected and TFA was in N2The mixture is evaporated by flowing down. Add excess Cold Et2The crude peptide was O precipitated and centrifuged. Pour Et2O, and the process was repeated 3 times. The precipitated crude peptide was dried and weighed and purified by preparative HPLC.
HPLC purification
The crude peptide (818mg) was dissolved in a solvent containing
H of 22% MeCN2O (6.4mL) in water and RP-HPLC (24% isocratic elution for 60 min) at Kinetex5Mu.l of 100A AXIA-packed C1821.2X 150mm semi-preparative column at a flow rate of 5 mL/min. The fractions containing the product were isolated and lyophilized to give product 1 as a fluffy white powder (58.5mg, 16.1% based on the resin used).
Radiolabelling
Will be equally divided64CuII(30-200MBq,0.1MNH4OAc, pH 6) is added to a solution comprising: Sar-PSMA1 (5. mu.g, 4.3X 10)-3μ mol) of MilliQ water, NH at pH54OAc (final concentration: 0.05M), ethanol (10%), and gentisic acid in MilliQ water (final concentration: 0.056%), and the pH (pH: 5) were measured. The reaction was incubated at room temperature for 30 minutes. After 30 minutes, an aliquot was analyzed by RP-HPLC to determine the product with > 98% radiochemical purity64Cu-Sar-PSMA。
Plasma stability
Add to 200. mu.L of fresh human plasma at 37 ℃64A saline solution of Cu-Sar-PSMA (100uL, 8.8MBq,<10% EtOH) and the mixture was incubated at 37 ℃ for 24 hours. After 24 hours, cold acetonitrile (600 μ L) was added. The precipitated serum proteins were separated by centrifugation (13000rpm) and 300. mu.L of the supernatant was removed and concentrated by evaporation. The solution was diluted with water (100. mu.L) and the product was analyzed by RP-HPLC.
Tumor imaging of LNCaP tumor-bearing mice
Studies in NSG (NOD SCID Gamma) mice bearing LNCaP tumors at 1, 6 and 22 hours post-injection64In vivo biodistribution of CuSarPSMA. At the time of 1 hour, the time of the reaction,64CuSarPSMA showed the highest uptake in the kidney, resulting in a low tumor/kidney ratio (fig. 5). However, the biodistribution data showed that at later time points, the kidney cleared rapidly and the tumor remained moderately. Although moderately retained in the tumor64Cu-Sar-PSMA, but there is a clear contrast due to the rapid clearance from the circulation and little background accumulation after 6 h. In addition, low uptake in other PSMA positive tissues (lung, spleen) allows64High tumor to background ratio of Cu-Sar-PSMA.
Example 2
CoSar(PSMA)2Synthesis of (2)
Synthesis of activated glutamic acid intermediates
The literature: duspara, P.A.; islam, m.s.; lough, a.j.; batey, R.A., Synthesis and resolution of N-alkyl carboxylic acids, displacement of N-methyl carboxylic acids as a methyl isocyanate equivalent.J. Org Chem 2012,77(22), 10362-8.
To the solution containing L-bis (tbu) Glu
A flask of HCl (3.56g, 12.04mmol, 1.0eq) and carbonyldiimidazole (2.15g, 13.24mmol, 1.1eq) was charged with DMF/MeCN (50mL) of 1: 5, mixing the mixture. The reaction was stirred at rt overnight. After stirring, the solvent was removed in vacuo and the remaining crude mixture was dissolved and purified by flash chromatography (mobile phase: 7: 3: 1 white spirit/chloroform/methanol, RF: -0.24, 30: 1 silica/crude mass ratio) to give the product as a white semi-crystalline powder (2.25g, 52.9% yield).
Synthesis of protected ureas
A solution of activated Glu intermediate (3.71g, 10.5mmol, 1.0eq) and DIPEA (1.83mL, 10.5mmol, 1eq)) in DCM (30mL) was added to a flask containing H-Lys (Fmoc) -OtBu & HCl (4.84g, 10.5mmol, 1.0eq) and stirred at room temperature overnight. The reaction mixture was washed with water X3, brine and MgSO4Dried and loaded onto an 80g sieve HP Silica column and purified by a Biotage Isolera automated flash chromatography purification system (mobile phase: 70: 30: 2.5 petroleum spirit/chloroform/methanol). Analysis by TLC (mobile phase: 7: 3: 1 white spirit/chloroform/methanol, RF:. about.0.30), combining, and removing solvent in vacuo gave 5.06g, 68% of the product as a yellow oil.
ESIMS+[M+H+]m/z710.386 (experiment), m/z710.401 (calculation).
Fmoc urea cleavage
To a flask containing protected urea (5.06g, 7.13mmol, 1eq) was added a 20% solution of diethylamine in MeCN (100mL) and the reaction mixture was stirred at room temperature for 7 hours. Aliquots were periodically removed to analyze reaction completion by MS. After 7 hours, diethylamine and MeCN were reduced to 5mL under vacuum, and 50mL of MeCN was additionally added to azeotropically evaporate the diethylamine 3 times by a rotary evaporator. The reaction mixture was again reduced to 5mL, 200mL of 50/50 water/MeCN was added, and the reaction mixture was lyophilized. The final product is used without further purification due to impurities resulting from incomplete removal of the dibenzofullerene moiety. (estimated purity 70%) ESIMS+[M+H+]m/z (experiment), m/z 488.333 (calculation).
Synthesis of 8-Aoc-ff linker on resin
The following Fmoc experimental protocol was used to prepare the 8-Aoc-ff linker.
General Fmoc deprotection protocol
The resin bound peptide was treated with 20% piperidine in DMF for 15 min × 3. The resin was then washed sequentially with DMF X3 and DCM X3.
Experimental protocol for Fmoc-aminocaprylic acid (Fmoc-8-Aoc-OH) loading on 2-CT resin
80mL of LPCM containing Fmoc-8-Aoc-OH (5.00g, 13.1mmol, 1.75eq) and DIPEA (2eq relative to AA) was added to 2-CT resin (7.50g, 1mmol/g, 1eq) and stirred. After 2 hours, 8mM LEOH was added and the resin was stirred for an additional 30 minutes. The resin was filtered and washed successively with DCM X3, DMF X3, DCM X3, MeOH X2 and Et2O × 2 washing and drying. The resin loading was calculated using the following equation to give 0.628mmol/g (6.16 mmol in total)
Experimental protocol for Fmoc-D-Phe-OH coupling to resin
Fmoc-D-Phe-OH (2eq) was activated using a solution of HATU (0.96 eq relative to AA) and DIPEA (2eq relative to AA) in NMP. After 5 minutes, the solution was added to the resin and stirred for at least 12 hours. The resin was filtered and washed sequentially with DMF X1, DCM X3 and DMF X3. Then, the coupling was repeated for at least 12 hours as described above, followed by filtration and washing with DMF × l, DCM × 3 and DMF × 3 in this order.
Resin cleavage protocol
The resin was washed several times with DCM and then transferred to two 50mL Falcon tubes. A solution of 5% TFA in DCM (75mL) was added to the resin and stirred at room temperature for 2 h. The resin was filtered and washed twice with 15mL of 5% TFA in DCM. Collecting the filtrate and adding to N2The reducing solvent is flowed down. The crude peptide was redissolved in 50/50 water/MeCN and lyophilized to give the crude peptide. The crude peptide was used without further purification.
Trifluoroacetamide protection
To a flask containing the crude peptide linker (1.35g, 2.98mmol, 1eq if pure) was added ethyl trifluoroacetate (0.532mL, 4.47mmol, 1.5eq) and DIPEA (1.04mL, 5.96mmol, 2eq) in MeOH (10 mL). The reaction was stirred at rt overnight and monitored by MS and analytical HPLC for complete conversion of the starting material. MeOH was reduced in vacuo and EtOAc/0.01MHCl was added to the reaction. The organic layer was separated and washed with 0.01MHCl 3 and brine, MgSO4Drying, and removal of the solvent in vacuo, dried to give the crude product (0.985g), which was used without further purification. Orbitrap-MS+[M+H+]M/z 550.253 (experiment), M/z 550.252 (calculation), [2M + H+]m/z 1099.498 (experiment), m/z 1099.497 (calculation).
Urea linker coupling
To a flask containing crude TFA-protected linker (0.985g, 1.79mmol, 1eq if neat) was added a solution of HATU (0.608g, 1.6mmol, 0.89eq) and DIPEA (0.56mL, 3.2mmol, 1.79eq) in DMF (5mL) and stirred at room temperature. After the lapse of 5 minutes, the reaction mixture was,the deprotected urea (about 1.5mmol) was added and the reaction was monitored by MS and analytical HPLC overnight. After 24 hours, K is added2CO3Aqueous solution and the reaction was heated to 60 ℃ overnight and monitored for the removal of the trifluoroacetamide protecting group. The reaction was diluted with water (150mL) and Et2And (4) carrying out O × 3 extraction. The ether fractions were combined, washed with water, 0.01M HCl X3 and brine, and MgSO4And (5) drying. The aqueous layer was acidified with 0.1M HCl and Et2O extraction, washing with water, 0.01M HCl and brine, and MgSO4And (5) drying. The ether layers were combined, the solvent removed in vacuo, and the crude product was dissolved in 80% MeCN in water and subjected to RP-HPLC (60-77% in 35 min) at Phenomenex Luna 5. mu.C1821.2X 250mm half column purification, flow rate of 8 mL/min. The fractions containing the product were collected and lyophilized to give the product as a fluffy white powder (49.6mg, 98% + purity). Orbitrap-MS+[M+H+]M/z 923.586 (experiment), [ M +2H+]M/z462.297 (calculated), [ M +2H+]m/z462.297 (experiment), m/z 462.296 (calculation).
(tBoc)4-5Synthesis of CoSar-Plus
(tBoc)4-5CoSar-Plus can be expressed as Ma, m.t.; cooper, m.s.; paul, r.l.; shaw, k.p.; karas, j.a.; scanlon, d.; white, j.m.; power, p.j.; donnelly, p.s.inorg Chem 2011,50,6701.
CoSar-(PSMA)2Synthesis of (2)
Adding a solution containing
(tBoc)4-5COSar-Plus (25.3mg, 0.027mmol, 1eq), HATU (20.4mg, 0.054mmol, 2eq) and DIPEA (18.7 μ L, 0.107mmol, 4eq.) in NMP solution (500 μ L). The mixture was shaken for 10 minutes to activate it, then added to a 2mL microwave bottle containing pure PSMA linker-urea (49.6mg, 0.054mmol, 2eq) in NMP (400 μ L).The reaction was stirred in a microwave reactor at 60 ℃ for 10 minutes, cooled and analyzed by MS and analytical HPLC to show complete consumption of starting material. To the reaction material was added 1.8mL of 72% aqueous MeCN solution and by RP-HPLC (60-90% over 60 min) at 5. mu.l Phenomenex LunaPurification was carried out on a C1821.2X 250mm semipreparative column at a rate of 8 mL/min. The product containing fractions were collected and lyophilized to give the protected product as a fluffy white powder (14.0mg, 5.08 μmol, 18.9% yield). The protected product was dissolved in 95% TFA water overnight, diluted with 50/50 MeCN/water, and lyophilized to give the tris-trifluoroacetate monohydrate salt as a white powder (12.1mg, 5.08. mu. mol) (RT: 10.3) min, 96.4% purity). Orbitrap-MS + [ M +2H +]M/z 1009.065 (experiment), M/z 1009.066 (calculation), [ M +3H +]m/z 673.046 (experiment), m/z 673.046 (calculation).
Radiolabelling
Will be provided with64CuIIAn aliquot of (100-400MBq, 0.01M HCl) was added to a solution containing 0.1M NH4OAc, pH5.5 (500. mu.L), ethanol (100. mu.L), MilliQ water (300. mu.L) and gentisic acid (1.2mg, 10mg/mL in MilliQ water), pH was determined (pH: 5). To this solution CoSar- (PSMA)2(20μg,8.4×10-3μ mol, 1mg/mL in MilliQ) and the reaction was incubated at room temperature for 30 minutes. After 30 minutes, an aliquot was analyzed by RP-HPLC to determine the product with > 97% radiochemical purity64Cu-CoSar(PSMA)2(rt:13.9min)。
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
Reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as, an acknowledgment or admission or any form of suggestion that prior publication (or information) or part of the common general knowledge in the field of endeavour to which this specification relates.
Claims (34)
1. A compound of formula (I) or a salt, complex, isomer, solvate or prodrug thereof:
wherein:
x is selected from H, OH, halogen, cyano, NO2、NH2Optionally substituted C1-C12Alkyl, optionally substituted amino, optionally substituted amide and optionally substituted aryl;
y is optionally substituted C1-C12Alkylene, wherein one or more methylene groups in the alkylene may be further optionally substituted with a group selected from amide, carbonyl, urea and thiourea;
m is 0,1 or 2; and is
n is 0,1 or 2.
2. The compound of claim 1, or a salt, complex, isomer, solvate or prodrug thereof, wherein: x is optionally substituted C1-C12An alkyl group.
3. The compound of claim 1, or a salt, complex, isomer, solvate or prodrug thereof, wherein:
x is an optionally substituted amide.
5. The compound of any one of claims 1-4, or a salt, complex, isomer, solvate or prodrug thereof, wherein:
y is a substituted alkylene group.
6. The compound of any one of claims 1-5, or a salt, complex, isomer, solvate or prodrug thereof, wherein:
y is an alkylene group substituted with an amide group.
7. The compound of claim 6, or a salt, complex, isomer, solvate or prodrug thereof, wherein:
y is alkylene further substituted by carbonyl.
9. The compound of any one of claims 1-4, or a salt, complex, isomer, solvate or prodrug thereof, wherein:
y is an unsubstituted alkylene group.
10. The compound of claim 9, or a salt, complex, isomer, solvate or prodrug thereof, wherein:
y is C1An alkylene group.
11. The compound of claim 9 or 10, or a salt, complex, isomer, solvate or prodrug thereof, wherein:
y is methylene.
12. The compound of any one of claims 1-11, or a salt, complex, isomer, solvate or prodrug thereof, wherein:
m is 1.
13. The compound according to any one of claims 1 to 12, or a salt, complex, isomer, solvate or prodrug thereof, wherein:
n is 1.
20. the compound of any one of claims 1 to 16, or a salt, complex, isomer, solvate or prodrug thereof, wherein the compound is coordinated with a metal ion.
21. The compound according to claim 17, or a salt, complex, isomer, solvate or prodrug thereof,
the metal ions are Cu, Tc, Gd, Ga, In, Co, Re, Fe, Au, Mg, Ca, Ag, Rh, Pt, Bi, Cr, W, Ni, V, Ir, Zn, Cd, Mn, Ru, Pd, Hg, Ti, Lu, Sc and Y.
22. The compound of claim 17 or 18, wherein the metal ion is a radionuclide.
23. The compound of any one of claims 17 to 19, wherein the metal ion is a copper ion.
24. The compound of any one of claims 17 to 20, wherein the metal ion is selected from60Cu、62Cu、64Cu and67Cu。
25. a composition comprising a compound of any one of claims 1 to 24 and a pharmaceutically acceptable excipient.
26. An aqueous composition for parenteral administration comprising a compound of any one of claims 1 to 24, wherein the composition further comprises: ethanol, gentisic acid or a salt thereof, and sodium chloride.
27. The aqueous composition of claim 26, wherein the compound of formula (I) is complexed with Cu ions.
28. The aqueous composition of claim 27, wherein the Cu ions are selected from60Cu、62Cu、64Cu and67Cu。
30. A method of treating or preventing a disorder in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 24 or a composition according to any one of claims 25 to 29.
31. The method of claim 29, wherein the disease is cancer.
32. The method of claim 30, wherein the condition is selected from breast cancer, colon cancer, lung cancer, ovarian cancer, prostate cancer, head and/or neck cancer, kidney, stomach, pancreatic cancer, brain cancer, hematologic malignancies, lymphomas, and leukemias.
33. The method of any one of claims 29 to 31, wherein the condition is prostate cancer.
34. A method of radioimaging a subject, the method comprising administering an effective amount of a compound according to any one of claims 1 to 24 or a composition according to any one of claims 25 to 29.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210956079.XA CN115322244A (en) | 2017-06-06 | 2018-06-05 | Radiopharmaceuticals, radioimaging agents and uses thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017902151 | 2017-06-06 | ||
AU2017902151A AU2017902151A0 (en) | 2017-06-06 | Radiopharmaceuticals, radioimaging agents, and uses thereof | |
PCT/AU2018/050555 WO2018223180A1 (en) | 2017-06-06 | 2018-06-05 | Radiopharmaceuticals, radioimaging agents, and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210956079.XA Division CN115322244A (en) | 2017-06-06 | 2018-06-05 | Radiopharmaceuticals, radioimaging agents and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110914274A true CN110914274A (en) | 2020-03-24 |
CN110914274B CN110914274B (en) | 2022-08-26 |
Family
ID=64565650
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880037177.5A Active CN110914274B (en) | 2017-06-06 | 2018-06-05 | Radiopharmaceuticals, radioimaging agents and uses thereof |
CN202210956079.XA Pending CN115322244A (en) | 2017-06-06 | 2018-06-05 | Radiopharmaceuticals, radioimaging agents and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210956079.XA Pending CN115322244A (en) | 2017-06-06 | 2018-06-05 | Radiopharmaceuticals, radioimaging agents and uses thereof |
Country Status (15)
Country | Link |
---|---|
US (4) | US10975089B2 (en) |
EP (2) | EP3634965B1 (en) |
JP (2) | JP7144451B2 (en) |
KR (1) | KR102644075B1 (en) |
CN (2) | CN110914274B (en) |
AU (1) | AU2018280338B2 (en) |
BR (1) | BR112019025881A2 (en) |
CA (1) | CA3066525A1 (en) |
DK (1) | DK3634965T3 (en) |
ES (1) | ES2943458T3 (en) |
FI (1) | FI3634965T3 (en) |
MX (2) | MX2019014758A (en) |
PL (1) | PL3634965T3 (en) |
PT (1) | PT3634965T (en) |
WO (1) | WO2018223180A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201504064D0 (en) | 2015-03-10 | 2015-04-22 | Accretion Biotechnology Ltd | Method and kits for preparing radionuclide complexes |
CN112423744A (en) | 2018-04-11 | 2021-02-26 | 透明医药有限公司 | Formulations and kits for radiation therapy and diagnostic imaging |
CN114423421A (en) * | 2019-05-24 | 2022-04-29 | 透明医药有限公司 | Preparation of PSMA developer |
WO2020252598A1 (en) * | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
WO2021087568A1 (en) * | 2019-11-08 | 2021-05-14 | The University Of Queensland | Radiolabelled targeting ligands |
JP2023523226A (en) * | 2020-04-29 | 2023-06-02 | ノバルティス アーゲー | Methods and kits for radiolabeling PSMA-binding ligands |
US20240050600A1 (en) * | 2020-08-14 | 2024-02-15 | Clarity Pharmaceuticals Ltd | Radiopharmaceuticals, uses thereof, and methods for the production thereof |
US20240018099A1 (en) * | 2020-11-19 | 2024-01-18 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
WO2022123462A1 (en) * | 2020-12-09 | 2022-06-16 | 3B Pharmaceuticals Gmbh | Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof |
US20240082435A1 (en) * | 2021-02-26 | 2024-03-14 | Telix International (Innovations) Pty Ltd | Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents |
EP4387944A1 (en) * | 2021-08-17 | 2024-06-26 | Clarity Pharmaceuticals Ltd | Radiopharmaceuticals, methods for the production thereof, and uses in treatment, diagnosis and imaging diseases |
KR20240115844A (en) * | 2021-11-24 | 2024-07-26 | 클라리티 파마슈티컬스 리미티드 | Compounds and compositions thereof for treatment of cancer |
WO2024031153A1 (en) * | 2022-08-11 | 2024-02-15 | Clarity Pharmaceuticals Limited | Dimeric radiopharmaceuticals, compositions thereof and uses thereof |
US20240189460A1 (en) | 2022-09-23 | 2024-06-13 | Nuclidium Ag | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof |
WO2024168386A1 (en) * | 2023-02-14 | 2024-08-22 | Clarity Pharmaceuticals Limited | Methods for the detection and diagnosis of cancers associated with overexpression of a psma receptor |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6869589B1 (en) * | 1999-01-05 | 2005-03-22 | Australian Nuclear Science & Technology Organization | Cryptate compounds and methods for diagnosis and therapy |
US20070048216A1 (en) * | 2005-08-23 | 2007-03-01 | Norenberg Jeffrey P | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma |
CN102300866A (en) * | 2008-12-02 | 2011-12-28 | 墨尔本大学 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals |
WO2013082656A1 (en) * | 2011-12-06 | 2013-06-13 | The University Of Melbourne | Cage amine ligands for metallo-radiopharmaceuticals |
CN103638536A (en) * | 2013-12-11 | 2014-03-19 | 东南大学 | Molecular probe and preparation method and application thereof |
US20140219915A1 (en) * | 2011-07-07 | 2014-08-07 | Australian Nuclear Science And Technology Organisation | Cryptate compounds |
-
2018
- 2018-06-05 KR KR1020197035829A patent/KR102644075B1/en active IP Right Grant
- 2018-06-05 ES ES18813763T patent/ES2943458T3/en active Active
- 2018-06-05 EP EP18813763.2A patent/EP3634965B1/en active Active
- 2018-06-05 CN CN201880037177.5A patent/CN110914274B/en active Active
- 2018-06-05 BR BR112019025881-7A patent/BR112019025881A2/en unknown
- 2018-06-05 MX MX2019014758A patent/MX2019014758A/en unknown
- 2018-06-05 FI FIEP18813763.2T patent/FI3634965T3/en active
- 2018-06-05 WO PCT/AU2018/050555 patent/WO2018223180A1/en unknown
- 2018-06-05 AU AU2018280338A patent/AU2018280338B2/en active Active
- 2018-06-05 EP EP23157733.9A patent/EP4209495A1/en active Pending
- 2018-06-05 CN CN202210956079.XA patent/CN115322244A/en active Pending
- 2018-06-05 US US16/619,073 patent/US10975089B2/en active Active
- 2018-06-05 CA CA3066525A patent/CA3066525A1/en active Pending
- 2018-06-05 PT PT188137632T patent/PT3634965T/en unknown
- 2018-06-05 PL PL18813763.2T patent/PL3634965T3/en unknown
- 2018-06-05 DK DK18813763.2T patent/DK3634965T3/en active
- 2018-06-05 JP JP2019565549A patent/JP7144451B2/en active Active
-
2019
- 2019-12-06 MX MX2022002401A patent/MX2022002401A/en unknown
-
2021
- 2021-03-10 US US17/198,131 patent/US11384088B2/en active Active
-
2022
- 2022-06-07 US US17/834,773 patent/US11970503B2/en active Active
- 2022-09-15 JP JP2022146714A patent/JP7506121B2/en active Active
-
2023
- 2023-08-11 US US18/233,135 patent/US20230382918A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6869589B1 (en) * | 1999-01-05 | 2005-03-22 | Australian Nuclear Science & Technology Organization | Cryptate compounds and methods for diagnosis and therapy |
US20070048216A1 (en) * | 2005-08-23 | 2007-03-01 | Norenberg Jeffrey P | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma |
CN102300866A (en) * | 2008-12-02 | 2011-12-28 | 墨尔本大学 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals |
US20140219915A1 (en) * | 2011-07-07 | 2014-08-07 | Australian Nuclear Science And Technology Organisation | Cryptate compounds |
WO2013082656A1 (en) * | 2011-12-06 | 2013-06-13 | The University Of Melbourne | Cage amine ligands for metallo-radiopharmaceuticals |
CN103638536A (en) * | 2013-12-11 | 2014-03-19 | 东南大学 | Molecular probe and preparation method and application thereof |
Non-Patent Citations (6)
Title |
---|
BRETT M. PATERSON ET AL.: "PET imaging of tumours with a Cu-64 labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotateoctreotate", 《DALTON TRANSACTIONS》 * |
CHIUN-WEI HUANG ET AL.: "Design, synthesis and validation of integrin α2β1-targeted probe for microPET imaging of prostate cancer", 《EUR J NUCL MED MOL IMAGING》 * |
ELENI GOURNI ET AL.: "Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer", 《MOL. PHARMACEUTICS》 * |
NICHOLAS A. ZIA ET AL.: "A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention", 《ANGEW. CHEM. INT. ED.》 * |
PAUL S. DONNELLY ET AL.: "Synthesis with coordinated ligands: biomolecule attachment to cage amines", 《J. CHEM. SOC., DALTON TRANS.》 * |
SHUANGLONG LIU ET AL.: "Development of Multi-Functional Chelators Based on Sarcophagine Cages", 《MOLECULES》 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110914274B (en) | Radiopharmaceuticals, radioimaging agents and uses thereof | |
KR102658933B1 (en) | Dual targeting compounds and their preparation methods and applications | |
US10646598B2 (en) | Cage-like bifunctional chelators, copper-64 radiopharmaceuticals and PET imaging using the same | |
JP6047581B2 (en) | Cage amine ligands for metal radiopharmaceuticals | |
AU2012350146B2 (en) | Functionalisation of cage amine ligands for metallo-radiopharmaceuticals | |
WO2023019303A1 (en) | Radiopharmaceuticals, methods for the production thereof, and uses in treatment, diagnosis and imaging diseases | |
RU2804297C2 (en) | Radiopharmaceuticals, radioimaging agents and their use | |
CN115175910A (en) | Radiolabelled targeting ligands | |
CN118271393B (en) | FAP-targeted dimeric compound, probe and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220118 Address after: New South Wales,Australia Applicant after: Transparent Medicine Co.,Ltd. Address before: 3010 Melbourne, Victoria, Australia Applicant before: THE University OF MELBOURNE |
|
GR01 | Patent grant | ||
GR01 | Patent grant |